BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 32445029)

  • 1. Expression of programmed death-ligand 1 (PD-L1) in human pituitary neuroendocrine tumor.
    Suteau V; Collin A; Menei P; Rodien P; Rousselet MC; Briet C
    Cancer Immunol Immunother; 2020 Oct; 69(10):2053-2061. PubMed ID: 32445029
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PD-L1 Expression in Small Cell and Large Cell Neuroendocrine Carcinomas of Lung: an Immunohistochemical Study with Review of Literature.
    Guleria P; Kumar S; Malik PS; Jain D
    Pathol Oncol Res; 2020 Oct; 26(4):2363-2370. PubMed ID: 32506394
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The expression profile of PD-L1 and CD8
    Wang PF; Wang TJ; Yang YK; Yao K; Li Z; Li YM; Yan CX
    J Neurooncol; 2018 Aug; 139(1):89-95. PubMed ID: 29680903
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased expression of programmed death ligand 1 (PD-L1) in human pituitary tumors.
    Mei Y; Bi WL; Greenwald NF; Du Z; Agar NY; Kaiser UB; Woodmansee WW; Reardon DA; Freeman GJ; Fecci PE; Laws ER; Santagata S; Dunn GP; Dunn IF
    Oncotarget; 2016 Nov; 7(47):76565-76576. PubMed ID: 27655724
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PD-L1 expression in neuroendocrine tumors of the lung.
    Tsuruoka K; Horinouchi H; Goto Y; Kanda S; Fujiwara Y; Nokihara H; Yamamoto N; Asakura K; Nakagawa K; Sakurai H; Watanabe SI; Tsuta K; Ohe Y
    Lung Cancer; 2017 Jun; 108():115-120. PubMed ID: 28625622
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PD-L1 Is Preferentially Expressed in PIT-1 Positive Pituitary Neuroendocrine Tumours.
    Turchini J; Sioson L; Clarkson A; Sheen A; Gill AJ
    Endocr Pathol; 2021 Sep; 32(3):408-414. PubMed ID: 33694064
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multiplexed immunofluorescence reveals potential PD-1/PD-L1 pathway vulnerabilities in craniopharyngioma.
    Coy S; Rashid R; Lin JR; Du Z; Donson AM; Hankinson TC; Foreman NK; Manley PE; Kieran MW; Reardon DA; Sorger PK; Santagata S
    Neuro Oncol; 2018 Jul; 20(8):1101-1112. PubMed ID: 29509940
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Clinical Significance of PD-L1/PD-1 Expression in Gastroenteropancreatic Neuroendocrine Neoplasia.
    Wang C; Yu J; Fan Y; Ma K; Ning J; Hu Y; Niu W; Dong X; Wu Y; Li E; Dong D
    Ann Clin Lab Sci; 2019 Sep; 49(4):448-456. PubMed ID: 31471333
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Programmed Death Ligand 1 (PD-L1) Status and Tumor-Infiltrating Lymphocytes in Hot Spots of Primary and Liver Metastases in Prostate Cancer With Neuroendocrine Differentiation.
    von Hardenberg J; Hartmann S; Nitschke K; Worst TS; Ting S; Reis H; Nuhn P; Weis CA; Erben P
    Clin Genitourin Cancer; 2019 Apr; 17(2):145-153.e5. PubMed ID: 30709785
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PD-L1 Expression in Tumor Cells Is an Independent Unfavorable Prognostic Factor in Oral Squamous Cell Carcinoma.
    de Vicente JC; Rodríguez-Santamarta T; Rodrigo JP; Blanco-Lorenzo V; Allonca E; García-Pedrero JM
    Cancer Epidemiol Biomarkers Prev; 2019 Mar; 28(3):546-554. PubMed ID: 30487133
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relationship of tumor PD-L1 (CD274) expression with lower mortality in lung high-grade neuroendocrine tumor.
    Inamura K; Yokouchi Y; Kobayashi M; Ninomiya H; Sakakibara R; Nishio M; Okumura S; Ishikawa Y
    Cancer Med; 2017 Oct; 6(10):2347-2356. PubMed ID: 28925087
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The therapeutic candidate for immune checkpoint inhibitors elucidated by the status of tumor-infiltrating lymphocytes (TILs) and programmed death ligand 1 (PD-L1) expression in triple negative breast cancer (TNBC).
    Tomioka N; Azuma M; Ikarashi M; Yamamoto M; Sato M; Watanabe KI; Yamashiro K; Takahashi M
    Breast Cancer; 2018 Jan; 25(1):34-42. PubMed ID: 28488168
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PD-L1 Expression in Pituitary Neuroendocrine Tumors/Pituitary Adenomas.
    Cossu G; La Rosa S; Brouland JP; Pitteloud N; Harel E; Santoni F; Brunner M; Daniel RT; Messerer M
    Cancers (Basel); 2023 Sep; 15(18):. PubMed ID: 37760441
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Progress of Immunotherapy in Refractory Pituitary Adenomas and Pituitary Carcinomas.
    Dai C; Liang S; Sun B; Kang J
    Front Endocrinol (Lausanne); 2020; 11():608422. PubMed ID: 33362722
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Program Death 1 Immune Checkpoint and Tumor Microenvironment: Implications for Patients With Intrahepatic Cholangiocarcinoma.
    Gani F; Nagarajan N; Kim Y; Zhu Q; Luan L; Bhaijjee F; Anders RA; Pawlik TM
    Ann Surg Oncol; 2016 Aug; 23(8):2610-7. PubMed ID: 27012989
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression and Prognostic Value of B7 Family Immune Checkpoints in Pancreatic Neuroendocrine Tumors.
    Mo S; Zong L; Chen X; Ban X; Li M; Lu Z; Yu S; Chen J
    Arch Pathol Lab Med; 2023 Feb; 147(2):193-201. PubMed ID: 35671167
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Programmed Death Ligand 1 (PD-L1) Expression in Epithelial Ovarian Cancer: A Comparison of Type I and Type II Tumors.
    Nhokaew W; Kleebkaow P; Chaisuriya N; Kietpeerakool C
    Asian Pac J Cancer Prev; 2019 Apr; 20(4):1161-1169. PubMed ID: 31030490
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Programmed death-ligand 1 expression and its associations with clinicopathological features, prognosis, and driver oncogene alterations in surgically resected lung adenocarcinoma.
    Takamochi K; Hara K; Hayashi T; Kohsaka S; Takahashi F; Suehara Y; Suzuki K
    Lung Cancer; 2021 Nov; 161():163-170. PubMed ID: 34600407
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Programmed death ligand 1 testing in non-small cell lung carcinoma cytology cell block and aspirate smear preparations.
    Noll B; Wang WL; Gong Y; Zhao J; Kalhor N; Prieto V; Staerkel G; Roy-Chowdhuri S
    Cancer Cytopathol; 2018 May; 126(5):342-352. PubMed ID: 29499101
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Programmed Cell Death Ligand (PD-L1) Expression in Stage II and III Lung Adenocarcinomas and Nodal Metastases.
    Uruga H; Bozkurtlar E; Huynh TG; Muzikansky A; Goto Y; Gomez-Caraballo M; Hata AN; Gainor JF; Mark EJ; Engelman JA; Lanuti MD; Mino-Kenudson M
    J Thorac Oncol; 2017 Mar; 12(3):458-466. PubMed ID: 27815126
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.